Homocysteine metabolism in endothelial cells of a patient homozygous for cystathionine β-synthase (CS) deficiency

Thrombosis and Haemostasis

Volumn 78, Issue 2, 1997, Pages 827-833

  Van Der Molen, E F ^a   Hiipakka, M J ^b   Van Lith Zanders, H ^a   Boers, G H J ^a   Van Den Heuvel, L P W J ^a   Monnens, L A H ^a   Blom, H J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; METHIONINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PYRIDOXINE; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

AMINO ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; CELL FUNCTION; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HIGH RISK PATIENT; HOMOCYSTINURIA; HUMAN; HUMAN CELL; INCUBATION TIME; KIDNEY; LIVER; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOSIS; UMBILICAL VEIN; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

EID: 0030872991     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657636     Document Type: Article

References (33)

1. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: The metabolic basis if inherited disease. Scriver CR, Beaudet AL, Sly WS, et al. (eds). New York: Mc-Graw-Hill 1995; pp 1279-327.
2. Kluijtmans LAJ, Van den Heuvel LPWJ, Boers GHJ, Stevens EMB, Frosst P, Van Oost BA, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
3. Kraus JP. Molecular basis of phenotype expression in homocystinuria. J Inher Metab Dis 1994; 17: 383-90.
4. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J Clin Invest 1996; 98; 1: 5-7.
5. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-6.
6. Blom HJ, Kleinveld HA, Boers GHJ, Demacker PNM, Hak-Lemmers HLM, Te Poele-Pothoff MTWB, Trijbels FJM. Lipid peroxidation and susceptibility of low-density lipoprotein to in-vitro oxidation in hyperhomocysteinemia. Eur J Clin Invest 1995; 25: 149-54.
7. Dudman NPB, Wilcken DEL, Stocker R. Circulating lipid hydroxy peroxide levels in human hyperhomocysteinemia. Arteriosclerosis and thrombosis 1993; 13: 512-6.
8. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, Den Ottolander GHJ. Urinary albumin secretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
9. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekes CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-8.
10. Pandolfi M. The role of fibrinolytic factors in ischaemia. Eye 1991; 5: 159-69.
11. Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993; 81; 3: 683-9.
12. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein-C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
13. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulphate expression in cultured porcine aorotic endothelial cells. J Clin Invest 1993; 92: 1381-6.
14. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-9.
15. Blom HJ, van der Molen EF. Pathobiochemical implications of hyperhomocysteinemia. Fibrinolysis 1994; 8: 86-7.
16. Refsum H, Christensen B, Djurhuus R, Ueland PM. Interaction between methotrexate,"rescue" agents and cell proliferation as modulators of homocysteine export from cells in culture. J Pharmacol Exp Ther 1991; 258; 2: 559-66.
17. Christensen B, Refsum H, Garras A, Ueland PM. Homocysteine remethylation during nitrous oxide exposure of cells cultured in media containing various concentrations of folates. J Phar Exp Therap 1992; 261; 3: 1096-105.
18. Christensen B, Rosenblatt DS, Chu RC, Ueland PM. Effect of methionine and nitrous oxide on homocysteine export and remethylation in fibroblasts from cystathionine synthase-deficient, cb1G and cb1E patients. Paediatric Research 1993; 35; 1: 3-9.
19. Ueland PM, Refsum H, Brattström L. Plasma homocysteine and vascular disease. In: Atherosclerotic Cardiovascular Disease, Haemostasis and Endothelial Function. Francis RB (ed). New York: Marcel Dekker Inc. 1992; pp 183-236.
20. Van der Molen EF, Van den Heuvel LPWJ, Te Poele-Pothoff MTWB, Monnens LAH, Eskes TKAB, Blom HJ. The effect of folic acid on the homocysteine metabolism in human umbilical vein endothelial cells (HUVECs). Eur J Clin Invest 1996; 26: 304-9.
21. Jaffe E, Nachmann RL, Becker CG, Minick CR. Culture of human endothelial cell derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745.
22. Oliver MH, Harrison NK, Bishop JE, Cole PJ, Laurent GJ. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Science 1989; 92: 513-8.
23. Te Poele-Pothoff MTWB, Van der Berg M, Franken DG, Boers GHJ, Jacobs C, de Kroon IFI, Eskes TKAB, Trijbels FJM, Blom HJ. Three different methods for the determination of total homocysteine in plasma. Ann Clin Biochem 1995; 32: 218-20.
24. Fowler B, Krus J, Packman S, Rosenberg LE. Homocystinuria. Evidence of three distinct classes of cystathionine β-synthase mutants in cultured fibroblasts. J Clin Invest 1978; 61: 645-53.
25. Lowry OH, Rosebrouhg NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
26. Ingerslev JA. Sensitive ELISA for von Willebrand Factor (vWF:Ag). Scand J Clin Lab Invest 1987; 47: 143-9.
27. Finkelstein JD. Methionine metabolism in mammals. J Nutr 1990; 1: 228-37.
28. Van Hinsbergh VWM. Regulation of the synthesis and secretion of Plasminogen Activators by endothelial cells. Haemostasis 1988; 18: 307-27.
29. Schleef RR, Loskutoff DJ. Fibrinolytic system of vascular endothelial cells. Haemostasis 1988; 18: 328-41.
30. Paleolog EM, Crossman DC, Mcvey JH, Pearson JD. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand Factor from endothelial cells. Blood 1990; 75; 3: 688-95.
31. De Groot PG, Willems C, Boers GHJ, Gonsalves MD, Van Aken WG, Van Mourik JA. Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 1983; 13: 405-10.
32. De Valk HW, Van Eeden MKG, Banga JD, Van der Griend R, De Groot E, Haas FJLM, Meuwissen OJAT, Duran M, Smeitink JAM, Bwee Tien Poll-The, De Klerk JBC. Evaluation of the presence of premature atherosclerosis in adults with heterozygosity for cystathionine β-synthase deficiency. Stroke 1996; 27: 6: 1134-6.
33. Frosst P, Blom HJ, Goyette P, Sheppard CA, Matthews RG, Boers GHJ, Den Heijer M, Kluijtmans LAJ, Van den Heuvel LPWJ, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.